GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CohBar Inc (OTCPK:CWBR) » Definitions » Capex-to-Operating-Cash-Flow

CohBar (CohBar) Capex-to-Operating-Cash-Flow : 0.00 (As of Jun. 2023)


View and export this data going back to 2015. Start your Free Trial

What is CohBar Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

CohBar's Capital Expenditure for the three months ended in Jun. 2023 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Jun. 2023 was $-1.80 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


CohBar Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for CohBar's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CohBar Capex-to-Operating-Cash-Flow Chart

CohBar Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CohBar Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CohBar's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, CohBar's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CohBar's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CohBar's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where CohBar's Capex-to-Operating-Cash-Flow falls into.



CohBar Capex-to-Operating-Cash-Flow Calculation

CohBar's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -10.446
=N/A

CohBar's Capex-to-Operating-Cash-Flow for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -1.803
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CohBar  (OTCPK:CWBR) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


CohBar Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of CohBar's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


CohBar (CohBar) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1455 Adams Drive, Suite 2050, Menlo Park, CA, USA, 94025
CohBar Inc is a biotechnology company. It is engaged in the research and development of mitochondria-based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. The product portfolio of the company includes drugs such as CB4209 and CB4211, SHLP-6, SHLP-2, and new MBTs, these address a broad range of age-related diseases, including obesity, fatty liver disease, Type-2 diabetes, cancer, cardiovascular and neurodegenerative diseases. Geographically all the operations of the group functioned through the region of the United States.
Executives
Stephanie Tozzo director C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Misha Petkevich director C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Joanne Yun director C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Joseph J. Sarret director, officer: Chief Executive Officer C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Carol Nast director C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Kenneth C Cundy officer: Chief Scientific Officer 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Jeffrey Francis Biunno officer: CFO, Treasurer and Secretary 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Steven B Engle officer: Chief Executive Officer C/O XOMA LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
David Greenwood director 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Phyllis Gardner director 618 MIRADA AVENUE, STANFORD CA 94305
Philippe Calais director C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
John Amatruda director 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Simon Allen officer: Chief Executive Officer C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Albion Fitzgerald director 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Jon Leland Stern director, officer: Chief Executive Officer 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025

CohBar (CohBar) Headlines

From GuruFocus

CohBar to Present at the H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 06-28-2022